Depression and other mood disorders occur in approximately 25 percent of terminal patients. Untreated, depression and mood disorders can have a significantly negative impact on patients andfamilies. Screeningfor depression can be done as easily as asking one question: “Areyou depressed?” A positive response to this question can be followed with one of the more extensive screening tools. Anxiety disorders can also have a negative effect on patients and their families. These can be identified by also using one of the validated screening tools. Use of the antidepressant medications for treating depression and, in some cases, anxiety disorders has not been well studied in hospice and palliative care. Some of the antidepressants can also serve as adjuvant therapy in pain management.
1. Lloyd-Williams M, Dennis M, Taylor F: A prospective study to determine the association between physical symptoms and depression in patients with advanced cancer. Palliat Med. 2004; 18: 558-563.
2.
2. Le Fevre P, Devereux J, Smith S, et al.: Screening for psychiatric illness in the palliative care inpatient setting: A comparison between the Hospital Anxiety and Depression Scale and the General Health Questionnaire-12. Palliat Med. 1999; 13: 399-407.
3.
3. Akechi T, Okuyama T, Sugawara Y, et al.: Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: Associated and predictive factors. J Clin Oncol. 2004; 22: 1957-1965.
4.
4. Lloyd-Williams M, Friedman T, Rudd N: A survey of antidepressant prescribing in terminally ill. Palliat Med. 1999; 13: 243-248.
5.
5. Block SD: Assessing and managing depression in the terminally ill patient. Ann Intern Med. 2000; 132: 209-218.
6.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000, p 356-356.
7.
7. Periyakoil VS, Hallenbeck J: Identifying and managing preparatory grief and depression at the end of life. Am Fam Physician. 2002; 65: 883-890.
8.
8. Lloyd-Williams M, Spiller J, Ward J: Which depression screening tools should be used in palliative care?Palliat Med. 2003; 17: 40-43.
9.
9. Lloyd-Williams M, Dennis M, Taylor F, et al.: Is asking patients in palliative care, “Are you depressed?” appropriate? Prospective study. BMJ. 2003; 327: 372-373.
10.
10. Holtom N, Barraclough J: Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing depression in palliative care?Palliat Med2000; 14: 219-220.
11.
11. Lloyd Williams M: Is appropriate to screen palliative care patients for depression?Am JHosp Palliat Care. 2002; 19(2): 112-114.
12.
12. Lloyd-Williams M, Dennis M, Taylor F: A prospective study to compare three depression screening tools in patients who are terminally ill. Gen Hosp Psychiatry. 2004; 26: 384-389.
13.
13. Lloyd-Williams M: Difficulties in diagnosing and treating depression in the terminally ill cancer patient. Postgrad Med2000; 76: 555-558.
14.
14. Hoyl MT, Alessi CA, Harker JO, et al.: Development and testing of a five-item version of the Geriatric Depression Scale. JAm Geriatr Soc. 1999; 47: 873-878.
15.
15. Chochinov HM, Wilson KG, Enns M, et al.: Desire for death in the terminally ill. Am JPsychiatry. 1995; 152: 1185-1191.
16.
16. Grov EK, Dahl AA, Fossa SD: Anxiety, depression, and quality of life in caregivers of patients with cancer in late palliative phase. Ann Oncol. 2005; 16(7): 1185-1191.
17.
17. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000, p 479-479.
18.
18. Barraclough J: ABC of palliative care: Depression, anxiety and confusion. BMJ. 1997; 315(22 November): 1365-1368.
19.
19. Potter WZ, Hollister LE: Antidepressant agents. In: Katzung BG (ed): Basic and Clinical Pharmacology, ed 9. New York: McGraw-Hill, 2003,482-495.
20.
20. Nelson JC: Tricyclic and heterocyclic drugs. In: Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology, ed 3. Washington, DC: American Psychiatric Publishing, 2004, pp 207-230.
22. Rosenbaum JF, Tollefson GD: Fluoxetine. In: Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology, ed 3. Washington, DC: American Psychiatric Publishing, 2004, 231-236.
23.
23. Herr KD, Nemeroff CB: Paroxetine. In: Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology, ed 3. Washington, DC: American Psychiatric Publishing, 2004, 259-282.
24.
24. Abramowicz M (ed): Which SSRI?Med Lett Drugs Ther2003; 45(1170).
25.
25. Bernard SA: The interaction of medications used in palliative care. Hematol Oncol Clin North Am. 2002; 16: 641-655.
26.
26. Micromedex Healthcare Series Vol. 125. Expires 9/2005. Accessed August 26, 2005.
27.
27. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al.: Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26(6): 1129-1134.
28.
28. Detke MJ, Wiltse CG, Mallinckrodt CH, et al.: Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-based controlled trial. Eur Neuropsychopharmacol. 2004; 14(6): 457-470.
29.
29. Golden RN, Dawkins K, Nicholas L: Trazodone and nefazodone. In: Schatzberg AF, Nemeroff,CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology, ed 3. Washington, DC: American Psychiatric Publishing, 2004, 315-325.
30.
30. Martinon-Torres G, Fioravanti M, Grimley Evans J: Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004(3): CD004990.
31.
31. Williams JW, Mulrow CD, Chiquette E, et al.: Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med. 2000; 132: 743-756.
32.
32. Guaiana G, Barbui C, Hotopf M: Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database of Syst Rev. 2003(2).
33.
33. Roose SP, Laghrissi-Thode F, Kennedy JS, et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAM4. 1998; 279: 287-291.
34.
34. Snow V, Lascher S, Mottur-Pilson C: Clinical guideline 1: Pharmacologic treatment of acute major depression and dysthymia. Ann Intern Med2000; 132: 738-742.
35.
35. Furukawa TA, Streiner DL, Young LT: Antidepressants and benzodiazepine for major depression. Cochrane Database Syst Rev. 2001(3).
36.
36. Potash M, Breitbart W: Affective disorders in advanced cancer. Hematol Oncol Clin North Am. 2002; 16: 671-700.
37.
37. Lynch ME: Antidepressants and analgesics: A review of randomized controlled trials. J Psychiatry Neurosci. 2001; 26(1): 30-36.
39. Dworkin RH, Backonja M, Rowbotham MC, et al.: Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60: 1524-1534.
40.
40. Sindrup SH, Bach FW, Madsen C, et al.: Venlafaxine versus imipramine in painful polyneuropathy: A randomized trial. Neurology. 2003; 60(8): 1284-1289.
41.
41. Goldstein DJ, Lu Y, Detke MJ, et al.: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005; 116(1-2): 109-118.
42.
42. Leo RJ, Barkin RL: Antidepressant use in chronic pain management: Is there a role for duloxetine?Prim Care Comp J Clin Psychiatry. 2003; 5: 118-123.
